Current Search Results Main Searc
Page Ask a Librarian Displa
Knowledge Base Help Logoff
Full Text
Save Article Text Email Article Text Print Preview
Table of Contents:
≪ Intrahospital transport of critically ill pediatric patients.
≫ Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: An
executive summary.
Abstract
Objective: The development of practice parameters for
intravenous analgesia and sedation for adult patients in the
Practice parameters for intravenous analgesia and sedation for adult
patients in the intensive care unit: An executive summary
ISSN: 0090-3493
Accession: 00003246-199509000-00021
Email Jumpstart
Find Citing Articles
≪ Table of Contents
About this Journal ≫
Author(s):
Shapiro, Barry A. MD FCCM; Warren, Jonathan MD
FCCM; Egol, Andrew B. DO FCCM; Greenbaum,
Dennis M. MD FCCM; Jacobi, Judith PharmD FCCM;
Nasraway, Stanley A. MD; Schein, Roland M. MD
FCCM; Spevetz, Antoinette MD; Stone, James R.
MD FCCM
Issue: Volume 23(9), September 1995, pp 1596-1600
Publication Type: [Special Article]
Publisher: © Williams & Wilkins 1995. All Rights Reserved.
Institution(s):
These practice parameters have been developed
by the Guidelines/Practice Parameters Committee
of the American College of Critical Care Medicine,
Society of Critical Care Medicine, and thereafter
reviewed by the Society's Council. These guidelines
reflect the official opinion of the Society of
Critical Care Medicine and should not be construed
to reflect the views of the specialty boards or any
other professional medical organization.
Editor's Note: As with previous guidelines published
in this journal, these guidelines have not
undergone traditional peer review. See Crit Care
Med 1991; 19:137 and 1992; 20:447.
Reproduced with permission from the Society of
Critical Care Medicine.
Links
Abstract
Complete Reference
页码,1/7Ovid: Practice parameters for intravenous analgesia and sedation fo...
2009-2-9http://ovidsp.tx.ovid.com/spa/ovidweb.cgi?&S=OOJBFPNFEIDDAHKNNCGLAAC...
intensive care unit (ICU) setting for the purpose of guiding
clinical practice.
Participants: A task force of more than 40 experts in
disciplines related to the use of analgesic and sedative agents in
the ICU was convened from the membership of the American
College of Critical Care Medicine (ACCM) and the Society of Critical
Care Medicine (SCCM).
Evidence: The task force members provided the personal
experience and determined the published literature (MEDLINE
articles, textbooks, pharmacopeias, etc.) from which consensus
would be sought. Published literature was reviewed and classified
into one of four predetermined categories, according to study
design and scientific value.
Consensus Process: The task force met several times as a
whole, and numerous times in smaller groups by teleconference,
over a 1-yr period to identify the pertinent literature and arrive at
consensus recommendations for the whole task force to discuss.
Consideration was given to the relationship between the weight of
scientific information and the experts' viewpoints. Over the next
year, draft documents were composed by a task force steering
committee and debated by the task force members until consensus
was reached by nominal group process. The task force draft was
then reviewed, assessed, and edited by the Board of Regents of the
ACCM. After steering committee approval, the draft document was
reviewed and approved by the SCCM Council.
Data Synthesis: To facilitate rapid communication of the six
recommendations contained within the complete and unabridged
practice parameter document, an executive summary was prepared
for publication by the ACCM Board of Regents, and this executive
summary was approved by the task force steering committee and
the SCCM Executive Council.
Conclusions: A consensus of experts provided six
recommendations with supporting data for intravenous analgesia
and sedation in the ICU setting: a) morphine sulfate is the
preferred analgesic agent for critically ill patients; b) fentanyl is
the preferred analgesic agent for critically ill patients with
hemodynamic instability, for patients manifesting symptoms of
histamine release with morphine, or morphine allergy; c)
hydromorphone can serve as an acceptable alternative to
morphine; d) midazolam or propofol are the preferred agents only
for the short-term (less than 24 hrs) treatment of anxiety in the
critically ill adult; e) lorazepam is the preferred agent for the
prolonged treatment of anxiety in the critically ill adult; f)
haloperidol is the preferred agent for the treatment of delirium in
the critically ill adult. This executive summary selectively presents
supporting information and is not intended as a substitute for the
complete document.
Library Holdings
Outline
z Abstract
z ANALGESIA
z ANALGESIC AGENTS
RECOMMENDED FOR ROUTINE USE
IN THE INTENSIVE CARE UNIT
{ Recommendation 1--Level 2:
Morphine Sulfate Is the
Preferred Analgesic Agent for
Critically Ill Patients.
{ Recommendation 2--Level 2:
Fentanyl Is the Preferred
Analgesic Agent for Critically
Ill Patients With Hemodynamic
Instability, for Patients
Manifesting Symptoms of
Histamine Release With
Morphine, or Morphine
Allergy.
{ Recommendation 3--Level 3:
Hydromorphone Can Serve as
an Acceptable Alternative to
Morphine.
z ANALGESIC AGENTS NOT
RECOMMENDED FOR THE
CRITICALLY ILL
z SEDATION
z SEDATIVE AGENTS RECOMMENDED
FOR ROUTINE USE IN THE
INTENSIVE CARE UNIT
{ Recommendation 4--Level 2:
Midazolam or Propofol Are the
Preferred Agents Only for the
Short-Term (less than 24 Hrs)
Treatment of Anxiety in the
Critically Ill Adult.
{ Recommendation 5--Level 2:
Lorazepam Is the Preferred
Agent for the Prolonged
Treatment of Anxiety in the
Critically Ill Adult.
{ Recommendation 6--Level 1:
Haloperidol Is the Preferred
Agent for the Treatment of
Delirium in the Critically Ill
Adult.
z AGENTS NOT RECOMMENDED FOR
ROUTINE SEDATION OF THE
CRITICALLY ILL
页码,2/7Ovid: Practice parameters for intravenous analgesia and sedation fo...
2009-2-9http://ovidsp.tx.ovid.com/spa/ovidweb.cgi?&S=OOJBFPNFEIDDAHKNNCGLAAC...
(Crit Care Med 1995; 23:1596-1600)
KEY WORDS: analgesia; sedation; intensive care unit; morphine
sulfate; fentanyl; hydromorphone; midazolam; propofol;
lorazepam; haloperidol
The American College of Critical Care Medicine of the Society of Critical Care Medicine has developed practice
parameters to assist healthcare providers in prescribing sedation and analgesia in the intensive care unit (ICU)
setting. These practice parameters are limited to adult patients requiring sustained analgesia/sedation of longer
than several hours duration, and do not consider one-time therapy, nonsystemic analgesic therapies such as
epidural techniques, or patients who are less than 12 yrs of age. To assist the practitioner in determining the
relative scientific authority of the cited references in the unabridged document, each reference is categorized as
listed in Table 1. The unabridged document makes six specific recommendations, and each recommendation has
been assigned a ``rating level'' Table 1 that reflects the weight of scientific evidence, expert opinion, and clinical
practice experience upon which the recommendation was based.
This executive summary is not intended to be, and must not be used as, a substitute or replacement for the
unabridged practice parameters document. Rather, this executive summary is intended to facilitate communication
of the document's six specific recommendations and the fundamental information upon which these
recommendations were based.
ANALGESIA
Analgesia connotes the absence of sensibility to pain or noxious stimuli in the conscious patient. Pain has
consequences in the critically ill patient that can lead to clinically significant physiologic responses such as
tachycardia, increased myocardial oxygen consumption, hypercoagulability, immunosuppression, and persistent
catabolism [1]. ICU patients commonly experience pain from pathology as well as from diagnostic and therapeutic
procedures, for which intravenous opiates are the mainstay of analgesic therapy. The opiates are central nervous
system mu opioid receptor agonists that invoke analgesia, sedation, respiratory depression, constipation, urinary
retention, nausea, and confusion. Opiates have little, if any, amnestic properties.
Some critically ill patients receive inadequate analgesia due to unwarranted concerns about inducing opiate
addiction. More commonly, inadequate analgesia in the ICU results from attempting to avoid certain side effects of
opiate analgesics that are prominent in the ICU population, such as: a) respiratory depression in spontaneously
breathing patients and in patients receiving partial ventilator support; b) hypotension, which is most likely to occur
in patients with hypovolemia; and c) gastric retention and ileus, which are common in critically ill patients and
enhanced by opiates. Despite these legitimate concerns, adequate analgesia must remain a primary goal in the care
of the critically ill.
z REFERENCES
Graphics
z Table 1
[Help with image viewing]
[Email Jumpstart To Image]
Table 1. Rating systems for citations and recommendations
页码,3/7Ovid: Practice parameters for intravenous analgesia and sedation fo...
2009-2-9http://ovidsp.tx.ovid.com/spa/ovidweb.cgi?&S=OOJBFPNFEIDDAHKNNCGLAAC...
ANALGESIC AGENTS RECOMMENDED FOR ROUTINE USE IN THE INTENSIVE CARE UNIT
Recommendation 1--Level 2: Morphine Sulfate Is the Preferred Analgesic Agent for Critically Ill Patients.
In the United States, morphine sulfate is the most frequently used intravenous analgesic agent in the ICU,
mainly because of low cost, potency, analgesic efficacy, and euphoric effect. Morphine has a half-life of 1.5 to 2
hrs after intravenous administration in normal subjects. In the ICU patient, distribution volume and protein binding
may be abnormal, resulting in either an exaggerated or diminished response. Morphine may induce histamine
release, causing hypotension and other adverse effects.
Morphine sulfate should be administered intravenously and titrated to effect. Therapy should generally start at
a loading dose of 0.05 mg/kg, administered over 5 to 15 mins. Most adults require 4 to 6 mg/hr after receiving an
adequate loading dose. With bolus therapy, redosing should be accomplished every 1 to 2 hrs; with continuous
infusion therapy, one or more loading doses are required.
Recommendation 2--Level 2: Fentanyl Is the Preferred Analgesic Agent for Critically Ill Patients With
Hemodynamic Instability, for Patients Manifesting Symptoms of Histamine Release With Morphine, or
Morphine Allergy.
Fentanyl (Sublimaze Registered Trademark, Janssen Pharmaceutica, Titusville, NJ) is a synthetic opiate with
greater potency and lipophilic properties than morphine, resulting in a faster onset of action. Fentanyl does not
cause histamine release, which may explain the reduced frequency of hypotension compared with morphine.
Intravenous fentanyl has a relatively short half-life of 30 to 60 mins due to rapid redistribution to peripheral
compartments [2]. However, prolonged administration leads to accumulation in peripheral compartments that
results in a progressive increase in half-life to 9 to 16 hrs [3]. Fentanyl has little euphoric effect, no active
metabolites, and does not crossreact in patients with morphine allergy.
Fentanyl should be administered by continuous intravenous infusion. Most patients will be adequately treated
with 1 to 2 micro gram/kg/hr. One or more loading doses of 1 to 2 micro gram/kg are generally required when
therapy is initiated.
Recommendation 3--Level 3: Hydromorphone Can Serve as an Acceptable Alternative to Morphine.
Hydromorphone (Dilaudid Registered Trademark, Knoll Pharmaceutical, Whippany, NJ) is a semisynthetic
morphine derivative with more potent analgesic/sedative properties than morphine and significantly less euphoria.
The dosage should be initiated at 0.5 mg and titrated by 0.5 mg increments, with most patients requiring 1 to 2 mg
every 1 to 2 hrs.
ANALGESIC AGENTS NOT RECOMMENDED FOR THE CRITICALLY ILL
Meperidine (Demerol Registered Trademark, Sanofi Winthrop Pharmaceuticals, New York, NY) has an active
metabolite, normeperidine, that may accumulate and produce central nervous system excitation [4]. Opiate
agonist-antagonists (nalbuphine, butorphanol, buprenorphine) are available for the relief of mild-to-moderate pain
and may reverse other opiate agents. Agonist-antagonists are not recommended for routine use in critically ill
patients [5]. Nonsteroidal anti-inflammatory drugs have no analgesic advantages over opiates and have potential
risks of gastrointestinal bleeding, bleeding secondary to platelet inhibition, and the development of renal
insufficiency [6].
SEDATION
Sedation (calming or allaying excitement) is indicated in the ICU setting for the primary treatment of anxiety
(psychophysiologic response to the anticipation of real or imagined danger) and agitation (excitement accompanied
by motor restlessness). The prototype intravenous sedative agent is diazepam (Valium Registered Trademark, Roche
Laboratories, Nutley, NJ, and others), a long-acting lipophilic benzodiazepine that rapidly penetrates the central
nervous system, allowing for the sedative effect to be seen within 2 to 3 mins and peak effect within 3 to 5 mins.
All parenteral benzodiazepines reliably cause anterograde amnesia (inability to form new memory) and have no
analgesic activity. The effects of a single diazepam dose abates rapidly as the drug redistributes to peripheral
tissues, while a more sustained effect is achieved with repeated administration due to the saturation of peripheral
compartments and central nervous system binding sites [7]. Diazepam is no longer recommended for routine use in
页码,4/7Ovid: Practice parameters for intravenous analgesia and sedation fo...
2009-2-9http://ovidsp.tx.ovid.com/spa/ovidweb.cgi?&S=OOJBFPNFEIDDAHKNNCGLAAC...
the ICU for the following reasons: a) pain and thrombophlebitis are common when administered by peripheral
vein injection; b) a scheduled intermittent dosing regimen may lead to excessive sedation unless an objective
monitor of the level of sedation is utilized before each dose; and c) dilution is required for continuous infusion,
which demands large volumes of fluid administration.
SEDATIVE AGENTS RECOMMENDED FOR ROUTINE USE IN THE INTENSIVE CARE UNIT
Recommendation 4--Level 2: Midazolam or Propofol Are the Preferred Agents Only for the Short-Term
(less than 24 Hrs) Treatment of Anxiety in the Critically Ill Adult.
The greater cost of these drugs is balanced by the rapidity with which their pharmacologic effects abate with
short-term therapy.
Midazolam (Versed Registered Trademark, Roche Laboratories) is a short-acting, water-soluble benzodiazepine
that becomes a lipophilic compound in the blood and that rapidly penetrates the central nervous system to produce
an onset of sedation (2 to 2.5 mins) similar to diazepam. Midazolam is similar to diazepam in all respects, except
for its brief duration of clinical effect due to rapid redistribution, a factor that favors continuous infusion for
maintaining sedation in the critically ill. Long-term administration results in a prolongation of the clinical effects of
the drug. A maintenance midazolam dosage of 0.03 mg/kg/hr serves well as a starting point, with dosage titrated
to effect over time. One or more bolus loading doses (0.03 mg/kg) are generally required when therapy is initiated.
Propofol (Diprivan Registered Trademark, Stuart Pharmaceuticals, Wilmington, DE) is an intravenous, general
anesthetic agent that has sedative, hypnotic, anxiolytic, and anterograde amnestic properties at subanesthetic
dosages. When propofol is utilized in subanesthetic dosages, it produces anxiolysis and possesses some anterograde
amnestic effects. When propofol infusion is compared with midazolam infusion in critically ill patients, the two
drugs are equally effective sedative agents [8]. The onset of action after a single subanesthetic intravenous dose of
propofol is rapid (1 to 2 mins) and its effect is brief (10 to 15 mins) due to its rapid central nervous system
penetration and subsequent redistribution. For these reasons, propofol is administered only by continuous infusion
when used for sedation. Long-term infusions result in accumulation within lipid stores, resulting in a prolonged
elimination phase with a half-life of up to 300 to 700 mins. However, subtherapeutic plasma concentrations are
maintained after discontinuation of the drug by rapid clearance mechanisms. Propofol is administered at an initial
infusion rate of 0.5 mg/kg/hr and titrated rapidly upward in increments of 0.5 mg/kg every 5 to 10 mins, according
to clinical response. Typical maintenance dosages are 0.5 to 3.0 mg/kg/hr. Propofol should be administered via a
central vein.
Recommendation 5--Level 2: Lorazepam Is the Preferred Agent for the Prolonged Treatment of Anxiety in
the Critically Ill Adult.
Lorazepam (Ativan Registered Trademark, Wyeth-Ayerst Laboratories, Philadelphia, PA, and others) is an
intermediate-acting benzodiazepine that is less lipophilic than diazepam, which decreases its potential for
peripheral accumulation [9]. Compared with midazolam, lorazepam is longer acting, causes less hypotension,
causes an equally effective anterograde amnesia, is lower in cost, and with prolonged administration produces
more rapid awakening [10]. Lorazepam is most conveniently administered by intermittent intravenous bolus
injection, but continuous intravenous infusion is an equally acceptable method of administration. The usual starting
dosage is 0.044 mg/kg every 2 to 4 hrs, as needed, but this requirement is highly variable. One or more loading
doses are generally required with continuous infusion therapy. Because lorazepam has a slightly delayed onset of
action, a single dose of midazolam or diazepam may be utilized to initiate sedative therapy when rapid sedation is
required.
Recommendation 6--Level 1: Haloperidol Is the Preferred Agent for the Treatment of Delirium in the
Critically Ill Adult.
Delirium is a state of reduced ability to appropriately respond to external stimuli, usually manifested as
disorganized thinking (rambling, incoherent/irrelevant speech), decreased level of consciousness, altered sensory
perception, disorientation, and/or altered level of psychomotor activity. Delirium is frequent in the ICU and is
often incorrectly termed ``ICU psychosis.'' Administration of opiates or benzodiazepines as initial therapy for
delirium may cause a paradoxical worsening of symptoms because of the further alteration in sensory perception
页码,5/7Ovid: Practice parameters for intravenous analgesia and sedation fo...
2009-2-9http://ovidsp.tx.ovid.com/spa/ovidweb.cgi?&S=OOJBFPNFEIDDAHKNNCGLAAC...
produced by these agents.
Haloperidol (Haldol Registered Trademark, McNeil Pharmaceutical, Raritan, NJ) is a butyrophenone neuroleptic
drug with proven efficacy in the treatment of delirium in the critically ill [11]. Although haloperidol has not been
approved by the U.S. Food and Drug Administration for intravenous administration, this route of administration has
been reported to be safe and effective [12] and is preferred in the critically ill patient to maximize bioavailability
and predictability [11]. Clinical effects are observed within 30 to 60 mins after intravenous administration and may
last 4 to 8 hrs. Haloperidol may cause QT prolongation on the electrocardiogram [13] and should be used with
caution in conjunction with other drugs th
本文档为【镇静剂使用指南】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑,
图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。